Skip to main content
ABSI logo

ABSI

Absci Corp
$10.60 -0.87 (-7.59%) At close · Jul 10
Market Cap
$1.65B
Shares
155,905,056

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.60 Open$11.37 Day$10.32–11.41 52W$2.24–12.06 Avg vol 30d7.3M Short int36.9M · 23.7% float · 3.4d Short vol56% Last earningsMay 7, 2026 DataJul 2021–Jul 2026 Filing10-Q · May 7
Up next
Next earnings call
Aug 12, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +148%
      above
      Price vs 50-day avg +46%
      above
      RSI (14) 61
      neutral
      MACD trend Negative
      52-week position 85%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +66%
      trailing
      6-month return +248%
      trailing
      YTD return +204%
      this year
      Relative strength +238%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $7 › 200d $4 — 50d above 200d
      Institutional flow Accumulating
      4 of 164 funds reported for Jun 30 · net +81.6K sh shares · +1 new
      Insider flow Accumulating
      Net +$349.6K over 90 days · 0% sells
      Short interest Rising
      23.69% of float · ▲ +10.7% MoM · 3.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      164 holders — near 3-yr high, broad support
      Squeeze score 71
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth −21%
      Y/Y
      EPS growth +11%
      Y/Y
      Free cash flow $-94.0M
      Balance sheet $16.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 105%
      annualized · 1-yr
      Max drawdown −54%
      past year
      ATR 9.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +148% Bullish
      Price vs 50-day avg
      +46% Bullish
      RSI (14)
      61 Neutral
      MACD trend
      Negative Bearish
      52-week position
      85% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $7 › 200d $4 — 50d above 200d
      Institutional flow Accumulating
      4 of 164 funds reported for Jun 30 · net +81.6K sh shares · +1 new
      Insider flow Accumulating
      Net +$349.6K over 90 days · 0% sells
      Short interest Rising
      23.69% of float · ▲ +10.7% MoM · 3.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      164 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $2 Now $11 · 85% 52-wk high $12
      vs 200-day avg +148% vs 50-day avg +46%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ABSI
      Absci Corp
      this stock
      $1.65B +203.7% -20.7% 23.7%
      ONC
      BeOne Medicines Ltd.
      $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      $54.85B +4.4% 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      165
      % held
      81.8%
      Reported
      4 of 164
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      136
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      36.9M
      Days to cover
      3.4d
      Change
      +3.6M sh
      View
      Short Volume
      Short vol %
      56%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      4
      Value
      $26
      As of
      Jun 9, 2026
      View
      Off-Exchange
      Off-exchange %
      45.8%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$349.6K
      Buyers / Sellers
      2 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $4.5M
      Net income (FY)
      $-115.2M
      EPS diluted
      $-0.84
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $98.9K
      Shares
      19.9K
      Filed
      Jun 13, 2024
      View
      Exempt Offerings
      Offering
      $70.0M
      Filed
      Mar 30, 2021
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ABSI -8.8% +66.1% +247.5% -8.5% +203.7%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -10.2% +62.1% +238.5% -9.6% +193.0%
      Key facts CIK 1672688 CUSIP 00091E109 13F (30d) 4 filings 4 filers Visit website Investor relations